Menu
Search
|

Menu

Close
X

Editas Medicine Inc EDIT.OQ (NASDAQ Stock Exchange Global Select Market)

36.46 USD
-- (--)
As of 1:30 AM IST
chart
Previous Close 36.46
Open --
Volume --
3m Avg Volume 338,153
Today’s High --
Today’s Low --
52 Week High 45.02
52 Week Low 15.28
Shares Outstanding (mil) 41.74
Market Capitalization (mil) 1,043.82
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.67 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY18
4
FY17
14
FY16
6
FY15
2
EPS (USD)
FY18
-0.673
FY17
-2.993
FY16
-3.031
FY15
-2.053
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
185.11
5.73
Price to Book (MRQ)
vs sector
5.53
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
26.42
16.72
LT Debt to Equity (MRQ)
vs sector
18.31
12.39
Return on Investment (TTM)
vs sector
-42.42
14.61
Return on Equity (TTM)
vs sector
-63.35
16.34

EXECUTIVE LEADERSHIP

James Mullen
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Katrine Bosley
President, Chief Executive Officer, Director, Since 2014
Salary: $450,000.00
Bonus: $222,750.00
Andrew Hack
Chief Financial Officer, Since 2015
Salary: $157,500.00
Bonus: --
Charles Albright
Chief Scientific Officer, Since 2016
Salary: $136,538.00
Bonus: $44,297.00
Gerald Cox
Chief Medical Officer, Since 2016
Salary: $100,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

11 Hurley St
CAMBRIDGE   MA   02141-2110

Phone: +1617.4019000

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).

SPONSORED STORIES